StockNews.AI
BMY
StockNews.AI
168 days

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

1. Bristol Myers Squibb invests $20 million in neurodegeneration research. 2. The investment advances Evotec's pre-clinical program, benefiting BMY overall.

2m saved
Insight
Article

FAQ

Why Bullish?

BMY's investment in promising neuroscience research may enhance its drug pipeline, influenced by successful historical partnerships in drug development.

How important is it?

This strategic payment underlines BMY's commitment to research that could yield high-return therapies and illustrates sustained growth interests.

Why Long Term?

The advancement in neurodegeneration research could lead to significant breakthroughs, contributing to future revenue growth and market position.

Related Companies

EVTNVSPFESNY
Ongoing strategic partnership advances joint pipeline in neurodegeneration research Evotec receives a $20 million payment to further progress research HAMBURG, DE / ACCESS Newswire / March 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN:DE0005664809; NASDAQ:EVO) today announced another major accomplishment in its long-standing neuroscience collaboration with Bristol Myers Squibb (NYSE: BMY). The latest scientific achievement in the partnership has triggered a research payment of US$20 m to Evotec, enabling further development of a promising pre-clinical programme in neurodegeneration.

Related News